Brinsupri approval sets new benchmark in respiratory care

Insmed’s Brinsupri has secured US FDA approval as the first therapy for non-cystic fibrosis bronchiectasis, offering targeted anti-inflammatory action without antibiotics. As the first DPP-1 inhibitor approved for a respiratory indication, it addresses a major unmet need, with potential to become the standard of care and expand into other inflammatory diseases. Backed by robust Phase III data, Brinsupri is forecast to generate $1.7 billion in sales by 2033, tapping into a bronchiectasis market projected at $3.7 billion. Its mechanism opens the door for broader applications in COPD, cystic fibrosis, and beyond, signalling a pivotal growth opportunity in respiratory medicine.

Read the full analysis.